Clinical Trials Logo

Clinical Trial Summary

The study will investigate the effect of personalized diet on blood glucose control in individuals with diabetes as compared with ADA diet.

The primary objective is to test whether personalized diets based on DayTwo's algorithm can improve glycemic control and metabolic health compared to standard ADA acceptable dietary approach for diabetes at the end of a 3-month intervention period.


Clinical Trial Description

The prevalence of diabetes type 2 estimated to 628 Million people in the world by 2045 and was announced by the International Diabetes Federation (IDF) as one of the biggest epidemics in the history. Complications of diabetics Type 2 can range from high blood sugar include heart disease, strokes, diabetic retinopathy which can result in blindness, kidney failure, and poor blood flow in the limbs which may lead to amputations. It is also linked to other manifestations, collectively termed the metabolic syndrome, including obesity, hypertension, non-alcoholic fatty liver disease, hypertriglyceridemia and cardiovascular disease .

As blood glucose levels are mainly affected by food consumption, the growing number of blood glucose abnormalities is likely attributable to nutrition. Indeed, dietary and lifestyle changes normalize blood glucose levels in 55% -80% of the cases. Therefore, maintaining normal blood glucose levels is critical for preventing diabetes and its metabolic complications.

Currently, there are no effective methods for predicting the postprandial glycemic response (PPGR) of people to food. The current practice of using the meal carbohydrate content is a poor predictor of the PPGR and has limited efficacy. The glycemic index (GI), which quantifies PPGR to consumption of a single tested food type, and the derived glycemic load have limited applicability in assessing the PPGR to real-life meals consisting of arbitrary food combinations and varying quantities, consumed at different times of the day, and at different proximity to physical activity and other meals. Indeed, studies examining the effect of diets with a low glycemic index on TIIDM risk, weight loss, and cardiovascular risk factors yielded mixed results . The limited success of GI measure is probably due to the fact that it is a general index, which does not take into consideration the large variation between individuals in their glycemic response to food. It can be concluded, therefore, that in order to control glycemic response of an individual, we should build a personally tailored diet which takes into account various factors.

Although genetic factors influence the levels of fasting blood glucose and glycemic response to food, these factors only explain approximately 10% of the variance in the population. Supporting this claim is the fact that the number of people with diabetes is increasing in recent years regardless of patients' genetic background. In contrast, environmental factors such as the composition of the intestinal bacteria and their metabolic activity may affect the glycemic response. The entire bacteria population in the digestive tract (microbiome) consist of ~1,000 species with a genetic repertoire of ~3 million different genes. The microbiome is directly affected by our diet and directly affect the body's response to food. This special relationship between the host and the intestinal flora is reflected by the composition of bacteria unique to type 2 diabetes and in the significant changes in the bacteria composition upon transition from a diet rich in fiber to a "Western" diet rich in simple sugars.

Recently, DayTwo developed a highly accurate algorithm for predicting the personalized glucose response to food for each person based on the PNP Study conducted by the Weizmann Institute. The algorithm's predictions are based on many personal measurements, including blood tests, personal lifestyle and gut bacteria. In a small-scale pilot study that was conducted by the Weizmann Institute using the algorithm, the researchers personally tailored dietary interventions to healthy and prediabetic people, which resulted in significantly improved PPGRs accompanied by consistent alterations to the gut microbiota. These findings led to hypothesize that tailoring personalized diets based on PPGRs predictions may achieve better outcomes in terms of controlling blood glucose levels and its metabolic consequences relative to the current standard nutritional therapy for diabetes. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03662217
Study type Interventional
Source DayTwo
Contact Rony Bikovsky
Phone +972542299300
Email rony.bikovsky@daytwo.com
Status Recruiting
Phase N/A
Start date October 28, 2018
Completion date March 2020

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Active, not recruiting NCT04954313 - Baseline Oral Health Study: UnCoVer the Connections to General Health Phase 4
Completed NCT01354925 - Management of Type-2 Diabetic Patients Treated With Insulin During the Ramadan Phase 4
Completed NCT01206725 - Exercise Study on Cardiac Function in Patients With Diabetes Mellitus Type 2 and Diastolic Dysfunction N/A
Completed NCT00997282 - A Study of OPC-262 in Patients With Type 2 Diabetes Phase 2/Phase 3
Completed NCT00637546 - Gait and Balance of Diabetes Type 2 Patients Phase 2/Phase 3
Completed NCT00464880 - Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy Phase 1/Phase 2
Withdrawn NCT02057497 - An Exploratory Clinical Trial to Generate Whole Blood Samples for Analysing Genetic Polymorphisms N/A
Active, not recruiting NCT05014204 - Safety and Feasibility of Novel Therapy for Duodenal Mucosal Regeneration for Type II Diabetes N/A
Completed NCT04276051 - Cryovagotomy Diabetes Trial N/A
Completed NCT02569684 - Effects of Prebiotics on GLP-1 in Type 2 Diabetes N/A
Active, not recruiting NCT01933529 - ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes) Phase 2
Terminated NCT01722474 - Assessment of Three Instruments for the Non-invasive Measurement of Arterial Stiffness. N/A
Completed NCT00977262 - Postprandial Inflammation and Fatty Acids N/A
Completed NCT00518427 - Evaluate Quality of Life in Type 2 Diabetes, Before and After Change to Insuline Glargine Phase 4
Recruiting NCT05378620 - Project Dulce for Filipino-Americans With Type 2 Diabetes N/A
Recruiting NCT03834207 - A Study of the Usefulness & Usability of a Healthcare IT System for Managing Multi-morbidity and Poly-pharmacy N/A
Active, not recruiting NCT05228067 - Enhancing Brain Health by tDCS in Persons With Overweight and Obesity N/A
Active, not recruiting NCT05689684 - Arabinoxylan-oligosaccharides (AXOS) for the Management of Type-2 Diabetes N/A
Recruiting NCT05527574 - Home-based Interventions for FrAilty preveNTion in AdultS With DIabeTes and Chronic Kidney Disease N/A